The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 18, 2024
Filed:
Aug. 19, 2020
Applicant:
The Rockefeller University, New York, NY (US);
Inventors:
Craig Stuart Pace, Pacifica, CA (US);
David D. Ho, New York, NY (US);
Assignee:
The Rockefeller University, New York, NY (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 47/68 (2017.01); C07K 16/10 (2006.01); C12N 15/113 (2010.01);
U.S. Cl.
CPC ...
C07K 16/2812 (2013.01); A61K 47/6839 (2017.08); C07K 16/1045 (2013.01); C07K 2317/41 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/94 (2013.01); C12N 15/1132 (2013.01);
Abstract
The disclosure is directed to a histidine-mutated anti-HIV antibody having one or more mutations at the residue Y53a, D58, K96, D97, N98, or T100a in the heavy chain of ibalizumab, and at the residue S26, L30, L33, Q89, Y92, S93 or Y94 in the light chain of ibalizumab. In addition, the disclosure also is directed to two histidine mutated variants with two mutations, one with mutations at the residues Y53a and Y94, and the other with mutations at the residues D58 and L30 in the heavy and light chains of ibalizumab, respectively.